These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 30730071)

  • 41. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
    Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
    J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
    Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN
    Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging CAR landscape for cancer immunotherapy.
    Lim FLWI; Ang SO
    Biochem Pharmacol; 2020 Aug; 178():114051. PubMed ID: 32446888
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An Assessment of the Effectiveness and Safety of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma Patients with Relapsed or Refractory Disease: A Systematic Review and Meta-Analysis.
    Pereira R; Bergantim R
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732213
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
    Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [CAR T-cell therapy for multiple myeloma].
    Zhou X; Einsele H; Danhof S
    Internist (Berl); 2021 Jun; 62(6):605-610. PubMed ID: 33942145
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current use of CAR T cells to treat multiple myeloma.
    Firestone RS; Mailankody S
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):340-347. PubMed ID: 38066841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma.
    Jindal V; Khoury J; Gupta R; Jaiyesimi I
    Am J Clin Oncol; 2020 May; 43(5):371-377. PubMed ID: 31990758
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma.
    Cornell RF; Costa LJ
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):e73-e75. PubMed ID: 30448457
    [No Abstract]   [Full Text] [Related]  

  • 50. Chimeric antigen receptor T-cell therapy for multiple myeloma.
    Wang Z; Chen C; Wang L; Jia Y; Qin Y
    Front Immunol; 2022; 13():1050522. PubMed ID: 36618390
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
    Lin L; Cho SF; Xing L; Wen K; Li Y; Yu T; Hsieh PA; Chen H; Kurtoglu M; Zhang Y; Andrew Stewart C; Munshi N; Anderson KC; Tai YT
    Leukemia; 2021 Mar; 35(3):752-763. PubMed ID: 32632095
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma.
    Xu J; Wang Q; Xu H; Gu C; Jiang L; Wang J; Wang D; Xu B; Mao X; Wang J; Wang Z; Xiao Y; Zhang Y; Li C; Zhou J
    J Hematol Oncol; 2018 Oct; 11(1):128. PubMed ID: 30348186
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimeric antigen receptor T cells for acute lymphoblastic leukemia.
    Frey NV
    Am J Hematol; 2019 May; 94(S1):S24-S27. PubMed ID: 30784101
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient.
    Wang LX; Yu XQ; Cao J; Lu YL; Luo M; Lei F; Tang Y; Fei XM
    Int J Hematol; 2021 Sep; 114(3):408-412. PubMed ID: 34009622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells.
    Shah UA; Smith EL
    Cancer J; 2019; 25(3):208-216. PubMed ID: 31135528
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cell-based immunotherapy approaches for multiple myeloma.
    Kriegsmann K; Kriegsmann M; Cremer M; Schmitt M; Dreger P; Goldschmidt H; Müller-Tidow C; Hundemer M
    Br J Cancer; 2019 Jan; 120(1):38-44. PubMed ID: 30518815
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
    Kegyes D; Constantinescu C; Vrancken L; Rasche L; Gregoire C; Tigu B; Gulei D; Dima D; Tanase A; Einsele H; Ciurea S; Tomuleasa C; Caers J
    J Hematol Oncol; 2022 Jun; 15(1):78. PubMed ID: 35672793
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chimeric antigen receptor T-cell therapy for multiple myeloma.
    Hosen N
    Int J Hematol; 2020 Apr; 111(4):530-534. PubMed ID: 31981097
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CARs in the Lead Against Multiple Myeloma.
    Ormhøj M; Bedoya F; Frigault MJ; Maus MV
    Curr Hematol Malig Rep; 2017 Apr; 12(2):119-125. PubMed ID: 28233151
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.